GTx And UTRF Enter Into Exclusive License Agreement To Develop SARD Drug Candidate To Treat Castration-Resistant Prostate Cancer
UTRF News
Memphis-based device Company Receives $4.6 Million Investment
A Memphis-based device company has received a $4.6 million investment for its latest product. Ariste Medical has received the funding to continue development of a drug-eluting hernia mesh intended to reduce the risk of intra-abdominal infection. After hernia surgery, the risk of infection ranges from 8 percent to 40 percent, depending on complexity of the case.
UTRF Tech Talk: Protecting Your Ideas
The University of Tennessee Research Foundation (UTRF) presents: Protecting Your Ideas.